Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of efavaleukin alfa in moderately to severely active ulcerative colitis
2022-001686-12Phase 2Active
- Sponsor
- Amgen
- Start
- Oct 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavaleukin alfa in autoimmune colitis, sponsored by Amgen. Primary endpoint: Treatment-emergent adverse events. Started Oct 2022; status: active.
02
Drugs
efavaleukin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-001686-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001686-12.